Keyhaven Capital Partners backs Miura Partners and Evolve Healthcare Partners’ acquisition of HTBA
- HTBA is a global leader in natural ingredients and active pharmaceutical production, specialising in citrus flavonoids and vitamin B12 for various industries
- This investment will target both organic and inorganic growth, further solidifying HTBA’s position as a leading platform for natural ingredients in the health and food sectors
- The transaction represents Keyhaven’s third investment in 2024
Keyhaven Capital Partners (“Keyhaven”), the specialist private equity firm dedicated to the European lower mid-market, backs Miura Partners (“Miura”) and Evolve Healthcare Partners (“Evolve”) in the acquisition of HealthTech BioActives (“HTBA”).
With nearly 50 years of history, HTBA is a global leader in the research, development, production and distribution of high-quality, naturally derived ingredients, such as citrus flavonoids and active forms of vitamin B12. These ingredients cater to the pharmaceutical and health supplements industries, as well as the food and beverage and livestock nutrition sectors.
HTBA is a pioneer of patented manufacturing processes which are solvent-free and carcinogen-free, implementing sustainability-focused innovations which minimise the use of natural resources, supporting consumer health and protecting the environment.
Based in Barcelona, Spain, HTBA operates a state-of-the-art manufacturing facility in Murcia, along with technical ideation labs in Barcelona and Cincinnati, Ohio. With products sold in over 60 countries, HTBA has a sizeable global reach and therefore has significant influence in the industry.
This transaction marks Keyhaven’s third investment in 2024 and the tenth within their latest fund, underscoring the firm’s commitment to supporting market-leading businesses in strategic sectors backed by market trends.
Teddy Mouawad, Partner and Co-Head of Investments at Keyhaven Capital Partners, commented: “We are pleased to collaborate with our long-term partners, Miura and Evolve, to support HTBA, a world-class manufacturer of natural active ingredients serving a diverse range of end-markets. This transaction aligns with our strategy of investing in businesses within defensive sectors with favourable dynamics. HTBA demonstrates best-in-class innovation and operational excellence, consistently achieving above-market growth and margins. Together with our partners who are leading experts within the sector, and HTBA’s highly experienced management team, we are committed to driving both organic and inorganic growth, to further bolster HTBA’s leading position in the industry.”
Jordi Sabé, Managing Partner at Evolve said: “We are very pleased to join forces with Miura in this exciting opportunity and thank Keyhaven for their support. We believe Miura’s strong track record and Evolve’s healthcare expertise represents a winning combination that is likely to benefit HTBA and its strong management team in the next growth cycle, thus ultimately benefiting the many patients able to live better lives as a result of their products.”
Jordi Alegre, Managing Partner at Miura said: “We are very pleased with our investment in HTBA, a leader in the strategic natural ingredients sector for the pharmaceutical and nutrition industries, with a strong track record in innovation, growth and sustainability. This investment aligns well with our mid-market buy-outs strategy, focusing on industry-leading companies with solid business models, strong growth potential and a top-tier management team.”
About Keyhaven Capital Partners
Keyhaven is a specialist private equity firm dedicated to the European lower mid-market, focused on co-underwriting transactions with local sponsors. With a diverse team, a network embedded in local markets and a flexible approach to deal making, Keyhaven works with niche industry leaders to accelerate growth, building robust, sustainable businesses that deliver for their investors, employees and local communities.
Since its foundation in 2003, Keyhaven has invested or advised on investments worth in excess of €2.2 billion, representing over 70 transactions across Europe.
About Miura Partners
Miura Partners is a purpose-driven private equity firm. With offices in Barcelona and Madrid, the firm specialises in investing in small and medium-sized family-owned and entrepreneurial companies. Miura provides attractive growth and innovation plans with a clear focus on sustainability and internationalization.
The firm currently manages assets exceeding €1.5bn and has completed more than 80 investments worth in excess of €4bn since its inception in 2008.
About Evolve Healthcare Partners
Evolve is a mid-market deal-by-deal private equity firm specialising in healthcare investments across Europe. Founded by former international healthcare executives and investors, Evolve focuses on specialty pharmaceuticals, healthcare services, MedTech, and Healthcare IT. Their operationally focused and hands-on investment strategy is designed to enhance growth profiles and deliver above industry average returns in a dynamic and resilient sector.
For all media enquiries, please contact:
Instinctif Partners
Keyhaven@instinctif.com
+44 20 7457 2020